A U.S. jury awarded Nektar Therapeutics $90 million in damages in its dispute with Eli Lilly over a fractured licensing arrangement for rezpegaldesleukin (rezpeg). The verdict followed a contract claim that Lilly breached duties tied to co-development, with the awarded amount coming in below the sum Nektar sought. The decision is a reminder that, even amid fast-moving clinical development cycles, partner economics and development stewardship can become binding litigation risk. It also shapes how similarly structured deals may be renegotiated or litigated in future. For Nektar, the outcome provides cash and vindication in a core strategic partnership dispute; for the broader market, it clarifies the potential financial exposure tied to implied obligations in collaborative licensing models.